Recent Updates — AAVXF

Abivax SA reported financial results for the six months ended June 30, 2026, including a net loss of €165.9 million driven by increased research and development expenses of €107.9 million and general and administrative costs of €30.4 million. The company completed an underwritten public offering on July 6, 2026, raising approximately $874.1 million in net proceeds, bringing total cash resources to over €1.1 billion. Abivax also repurchased all outstanding royalty certificates for $90 million in May 2026 and announced executive leadership changes, with Chris Rabbat succeeding Fabio Cataldi as Chief Medical Officer and Tim Kelly appointed as Chief Technical Officer. The company remains on track to submit its New Drug Application for obefazimod in ulcerative colitis by the end of 2026 following positive Phase 3 trial results. Abivax is a clinical-stage biotechnology company developing therapeutics for chronic inflammatory diseases.

Abivax SA announced positive Phase 3 ABTECT 44-week maintenance trial results for obefazimod in treating moderate to severely active ulcerative colitis, meeting the primary endpoint of placebo-adjusted clinical remission at Week 44 for both the 25 mg (∆39.3%) and 50 mg (∆40.3%) doses. The trial also reported a 10.4% placebo clinical remission rate and met all key secondary endpoints. The company intends to submit a New Drug Application to the FDA in late Q4 2026.